trial

Clinical Trial of Dipyridamole in Schizophrenia

NCTId NCT00349973
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 29 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2008-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2001-05
Primary completion
2008-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
DipyridamoleOlanzapine

Sponsors

University of Maryland, Baltimore CountyLead Sponsor

Investigators

2
Ikwunga Wonodi, MDStudy Director
Gunvant K Thaker, MDPrincipal Investigator

Sites

1 total
Baltimore, United States

Facts & assertions

4 sourced
Enrollment
29
Phase
NA
Primary Completion Date
2008-09
Status
COMPLETED
relationships
The graph out of here
drug
Dipyridamole
drug
Olanzapine
drug
lead_sponsor
University of Maryland, Baltimore County
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Ikwunga Wonodi, MD
person
Gunvant K Thaker, MD
person